Kapidin

Lercanidipine Hydrochloride, the active ingredient in Kapidin, is a calcium channel blocker presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure in adults with essential hypertension by causing vasodilation of peripheral arteries. The drug is approved in the European Union and follows EU pharmaceutical quality guidelines.

GNH USA supplies Kapidin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable access to high‑quality medicines across multiple continents, supporting healthcare providers in delivering effective cardiovascular care.

Kapidin (lercanidipine) is used to manage conditions within the hypertension disease family.

- Essential hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Isolated systolic hypertension: provides effective blood pressure control in patients with elevated systolic readings. - Hypertension in elderly patients: offers once‑daily dosing with a favorable tolerability profile.

Kapidin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported in many patients. - Flushing: transient facial warmth and redness. - Peripheral edema: swelling of ankles or lower legs. - Dizziness: sensation of light‑headedness, especially after standing.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue that may compromise airway. - Severe hypotension: marked drop in blood pressure causing faintness. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzymes indicating liver injury.

Before initiating Kapidin, several precautionary measures should be considered to ensure safe use. - Blood pressure monitoring: check baseline and periodic readings to assess efficacy. - Hepatic function: evaluate liver enzymes in patients with known liver disease. - Elderly patients: start at low dose and monitor for edema. - Concomitant CYP3A4 inhibitors: avoid or adjust dose when used with strong inhibitors. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Kapidin can interact with other medicines, altering its antihypertensive effect or increasing adverse reactions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise lercanidipine plasma levels. - Other calcium channel blockers (e.g., amlodipine, nifedipine): additive vasodilatory effect can cause severe hypotension. - Grapefruit juice: potent CYP3A4 inhibition leading to increased drug exposure.

Moderate Interactions (Monitor Closely): - Diuretics: combined effect may enhance blood pressure reduction, requiring dose adjustment. - Beta‑blockers: may mask tachycardia that signals hypotension. - ACE inhibitors or ARBs: additive antihypertensive effect may necessitate closer monitoring.